Palatin Technologies, Inc. (LON:0KF3)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 12.87M +122.5% |
| Revenue (ttm) | 9.76M +3,581.2% |
| Net Income | -4.73M |
| EPS | -2.31 |
| Shares Out | 1.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3 |
| Open | 8.24 |
| Previous Close | 10.59 |
| Day's Range | 8.24 - 9.80 |
| 52-Week Range | 5.75 - 27.71 |
| Beta | -0.10 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 18, 2026 |
About Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company als... [Read more]
News
Palatin Technologies Slides: Corporate presentation
Palatin Technologies has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It
Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired hypo...
Palatin Technologies Proxy statement: Proxy filing
Palatin Technologies filed a proxy statement on June 25, 2026, providing details for shareholder voting and corporate governance matters.
Palatin Technologies Is Pursuing the Next Generation of MC4R. ...
Palatin Technologies Is Pursuing the Next Generation of MC4R. Rhythm Just Reinforced Why That Matters
Palatin Technologies Slides: Corporate presentation
Palatin Technologies has posted slides in relation to its latest quarterly earnings report, which was published on May 29, 2026.
Palatin announces approval of its common stock by Nasdaq
Palatin (PTN) Technologies announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq…
Palatin to Begin Trading on Nasdaq Stock Exchange
PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the ...
Palatin price target lowered to $47.50 from $50 at Alliance Global
Alliance Global lowered the firm’s price target on Palatin (PTN) to $47.50 from $50 and keeps a Buy rating on the shares. After the company’s quarterly report, the firm made…
Palatin Technologies Earnings Call Transcript: Q3 2026
Q3 FY2026 saw a significant revenue boost from licensing, improved net loss, and a strong cash position. Lead obesity therapies are advancing, with IND submissions planned for late 2026 and early 2027, supported by strategic partnerships and a focus on best-in-class selectivity.
Palatin Technologies Earnings release: Q3 2026
Palatin Technologies released its Q3 2026 earnings on May 13, 2026, summarizing the period's financial results.
Palatin Technologies Quarterly report: Q3 2026
Palatin Technologies has published its Q3 2026 quarterly earnings report on May 13, 2026.
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerability and long-term use, and key IND submissions targeted in calendar 2026 and 2027 Programs target rar...
Palatin Technologies Slides: Corporate presentation
Palatin Technologies has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Palatin Technologies Slides: Corporate presentation
Palatin Technologies has posted slides in relation to its latest quarterly earnings report, which was published on March 6, 2026.
Palatin Technologies' Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline ...
Palatin Technologies' Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline (NYSE: PTN)
Palatin Technologies Earnings Call Transcript: Q2 2026
Advanced rare obesity pipeline with strengthened finances from a public offering and asset sub-licensing. Cash runway extends beyond March 2027, with key clinical milestones ahead and reduced operating expenses expected next quarter.
Palatin Technologies Earnings release: Q2 2026
Palatin Technologies released its Q2 2026 earnings on February 17, 2026, summarizing the period's financial results.
Palatin Technologies Quarterly report: Q2 2026
Palatin Technologies has published its Q2 2026 quarterly earnings report on February 17, 2026.
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Advancing differentiated MC4R-based obesity programs into clinical development Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with a primary focus on hypothalamic obesity a...
Palatin Technologies Slides: Corporate presentation
Palatin Technologies has posted slides in relation to its latest quarterly earnings report, which was published on February 13, 2026.
Palatin Technologies Targets Hypothalamic Obesity as Next Frontier Beyond GLP-1s (NYSE: PTN)
Palatin Technologies Targets Hypothalamic Obesity as Next Frontier Beyond GLP-1s (NYSE: PTN)
Palatin Technologies Inc trading resumes
11:22 EST Palatin (PTN) Technologies Inc trading resumes
Palatin Technologies Inc trading halted, volatility trading pause
11:17 EST Palatin (PTN) Technologies Inc trading halted, volatility trading pause
JANUS HENDERSON GROUP PLC Acquires Shares in Palatin Technologies Inc
JANUS HENDERSON GROUP PLC Acquires Shares in Palatin Technologies Inc
Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals
Laidlaw initiated coverage of Palatin with a Buy rating and $60 price target. Palatin (PTN) is a clinical stage biotech company focusing on developing melanocortin receptor based therapeutics, the ana...